In 2023, the import of insulin in dosage forms to China stood at a significant level, providing a foundation for future forecasts. From 2024 to 2028, import volumes are forecasted to increase steadily from 1.6861 million kilograms to 1.8697 million kilograms. On a year-on-year basis, variations are as follows: a 2.8% increase from 2024 to 2025, a 2.7% increase from 2025 to 2026, a 2.6% increase from 2026 to 2027, and a 2.4% increase from 2027 to 2028. Analyzing trends over the last two years reveals consistent growth, whereas the compound annual growth rate (CAGR) over the forecast period reflects an average increase of approximately 2.6% per year.
Future trends to watch for include the potential impacts of regulatory changes, advancements in diabetes treatment technologies, and fluctuations in global insulin supply chains. Monitoring these factors will be crucial for assessing future import needs and ensuring the availability of insulin in the Chinese market.
